Our New Drugs

Developed by Chong Kun Dang's own technology, Duvie Tablet (ingredient name: Lobeglitazone) is Korea’s 20th new drug which was introduced on February 1, 2014.

As the very first insulin resistance improving agent developed in Korea, Duvie Tablet is a drug that improves insulin resistance specifically for type 2 diabetic patients who secrete insulin but have poor insulin sensitivity in their organs, making them less able to utilize insulin. Duvie Tablet has a relatively low risk of hypoglycemia as it is simply designed to improve insulin resistance, rather than forcing the release of insulin from the pancreas. It is a product that preserves and improves pancreatic beta-cell function. In 2016, Chong Kun Dang developed the metformin combination product known as Duvimet XR Tablet in an effort to improve diabetic patients’ quality of life by increasing the medication compliance and making them available in various dosages and smaller forms. Chong Kun Dang will continue to conduct various researches to prepare a foundation for effectiveness and safety of the drugs. We promise to be a leader in the TZD industry this way.

Camtobell Inj is Korea’s third anti-cancer drug, and it was developed by Chong Kun Dang with its own technology. Its ingredient name is Belotecan.

Camtobell Inj is an enzyme inhibitor of the Topoisomerase-I enzyme, which is widely found in cancer cells. Camtobell Inj was developed by semi-synthesizing Camptothecin that is extracted from the rare trees native to China and India.
The indications are recurrent ovarian cancer and small cell lung cancer. Our individual clinical results showed a high response rate of 45% in ovarian cancer and 42.9% in small cell lung cancer. Also, Camtobell Inj showed superior efficacy compared to existing treatments in the later clinical trials of ovarian cancer. It successfully extended the survival by approximately one year.